SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 32,724.85 |
| Enterprise Value ($M) | 33,304.16 |
| Book Value ($M) | 1,595.31 |
| Book Value / Share | 19.62 |
| Price / Book | 20.51 |
| NCAV ($M) | -298.23 |
| NCAV / Share | -3.67 |
| Price / NCAV | -109.73 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.34 |
| Return on Assets (ROA) | 0.26 |
| Return on Equity (ROE) | 0.57 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.95 |
| Current Ratio | 1.31 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,399.90 |
| Assets | 3,293.44 |
| Liabilities | 1,698.13 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 3,897.50 |
| Operating Income | 1,128.34 |
| Net Income | 887.87 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 929.00 |
| Cash from Investing | -207.06 |
| Cash from Financing | -878.07 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 9.40 | -16.07 | |
| 13G/A | Vanguard Group Inc | 11.78 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 325,064 | 859,920 | 37.80 | |
| 233,345 | 723,890 | 32.23 | |
| 318,525 | 853,035 | 37.34 | |
| 254,430 | 779,066 | 32.66 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| HOWL – Werewolf Therapeutics, Inc. | HUMA – Humacyte, Inc. |
| IBRX – ImmunityBio, Inc. | IDYA – IDEAYA Biosciences, Inc. |
| IFRX – InflaRx N.V. |
Financial data and stock pages provided by
Fintel.io